SC
MBX

Shay Capital’s MBX Biosciences MBX Stock Holding History

Shay Capital’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,133
Closed -$363K – 447
2025
Q1 		$363K Buy
+49,133
New +$519K 0.05% 179
2024
Q4 		– Sell
-15,000
Closed -$390K – 469
2024
Q3 		$390K Buy
+15,000
New +$343K 0.06% 189

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Shay Capital's MBX Position: Q2 2025 in Review

Shay Capital sold out of MBX Biosciences (MBX) in Q2 2025, closing a stake of 49,133 shares — an estimated $363K sold.

Shay Capital first reported a position in MBX in Q3 2024 and held it in 2 quarters. The position peaked at $390K in Q3 2024. 88 funds tracked by Wall St. Rank hold MBX as of Q2 2025.

  • Shay Capital reported no remaining MBX Biosciences position as of Q2 2025 after selling out during the quarter.
  • Shay Capital sold 49,133 MBX Biosciences shares in Q2 2025, an estimated $363K.
  • Shay Capital first reported a position in MBX Biosciences in Q3 2024 and held it in 2 quarters.
  • Shay Capital's MBX Biosciences position peaked at $390K in Q3 2024.
  • 88 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.